Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Disorders of Hemostasis01:24

Disorders of Hemostasis

2.6K
Hemostasis, the process that stops bleeding after a blood vessel injury, is crucial for maintaining the integrity of the circulatory system. However, disorders of hemostasis can disrupt this delicate balance, leading to either excessive clotting or bleeding. These disorders can be broadly classified into thromboembolic disorders and bleeding disorders.
Thromboembolic Disorders
Two factors primarily cause thromboembolic conditions.
2.6K
Introduction to Hemostasis01:05

Introduction to Hemostasis

15.6K
Hemostasis is a complex physiological process that prevents excessive bleeding when a blood vessel is injured. It's crucial for maintaining the integrity of the circulatory system, as it ensures that our blood remains fluid while still within the vascular network and yet clots to prevent blood loss upon vessel injury.
The three phases of hemostasis involve many clotting factors present in plasma and several substances released by platelets and injured tissue cells. It is a fast, localized,...
15.6K
Anticoagulant Drugs: Low-Molecular-Weight Heparins01:30

Anticoagulant Drugs: Low-Molecular-Weight Heparins

2.2K
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
2.2K
Extrinsic and Intrinsic Pathways of Hemostasis01:20

Extrinsic and Intrinsic Pathways of Hemostasis

14.4K
Blood clotting or coagulation involves extrinsic and intrinsic pathways, which ultimately merge into the common pathway, forming a fibrin clot.
The Extrinsic Pathway
The extrinsic pathway of coagulation is typically initiated by tissue damage that exposes blood to tissue factor (TF), a protein released by the damaged tissue cells outside the blood vessels—this interaction with TF triggers biochemical reactions involving specific clotting factors. The key player here is Factor VII, which...
14.4K
Venous Thrombosis IV: Nursing Management01:30

Venous Thrombosis IV: Nursing Management

341
Nursing management begins with a thorough assessment of the patient's health history. Key factors include trauma to veins, peripherally inserted central catheters, varicose veins, recent pregnancy or childbirth, surgery, bacteremia, prolonged bed rest, atrial fibrillation, COPD, heart failure, cancer, coagulation disorders, myocardial infarction, spinal cord injury, stroke, prolonged travel, recent bone fractures, and dehydration. Review medication intake, particularly oral contraceptives,...
341
Esophageal Varices-II: Clinical Features and Management01:28

Esophageal Varices-II: Clinical Features and Management

702
Esophageal varices often manifest as gastrointestinal bleeding episodes, presenting symptoms like hematemesis (vomiting of blood), hematochezia (passing fresh blood via the rectum), and melena (black, tarry stools). Other signs can include weight loss, anorexia, abdominal discomfort, jaundice, pruritus, altered mental status, and muscle cramps.
In the initial assessment, a thorough review of the patient's medical history is vital to identify risk factors such as liver disease, alcohol...
702

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Subchondral Bone Injections for the Treatment of Knee Osteoarthritis.

The archives of bone and joint surgery·2026
Same author

Clinical, Functional and Radiological Results of Bicondylar Tibial Plateau Fractures (AO41.C) Treated by Osteosynthesis with Plates and Screws.

The archives of bone and joint surgery·2026
Same author

Circumstances that Increase the Risk of Periprosthetic Joint Infection after Total Knee Arthroplasty.

The archives of bone and joint surgery·2026
Same author

Is Pharmacologic Prophylaxis for Venous Thromboembolism Necessary in People With Hemophilia After Total Knee and Hip Arthroplasty?

The archives of bone and joint surgery·2026
Same author

Robotic-assisted Total Knee Arthroplasty versus Conventional Total Knee Arthroplasty.

The archives of bone and joint surgery·2026
Same author

Total Ankle Replacement in Hemophilia.

The archives of bone and joint surgery·2025
Same journal

Cardiorenal Hemodynamic Effects of SGLT2 Inhibitors Across Heart Failure Phenotypes: A Structured Narrative Review.

Cardiovascular & hematological disorders drug targets·2026
Same journal

Explainable Hybrid Deep Learning Framework for Cardiovascular Disease Prediction and Clinical Decision Support.

Cardiovascular & hematological disorders drug targets·2026
Same journal

Catestatin as a Marker of Cardiovascular Diseases.

Cardiovascular & hematological disorders drug targets·2026
Same journal

IgG Kappa Multiple Myeloma with Cutaneous Plasmacytoma and Hypereosinophilic Leukocytosis in a Young Patient: A Rare Case Report.

Cardiovascular & hematological disorders drug targets·2026
Same journal

Clinical and Hematological Profile of Rare Manifestations Associated with Malaria: A Retrospective Observational Study.

Cardiovascular & hematological disorders drug targets·2026
Same journal

Effective Lowering of Lipoprotein (a) - A New Frontier in Cardiovascular Risk Reduction.

Cardiovascular & hematological disorders drug targets·2026
See all related articles

Related Experiment Video

Updated: Mar 9, 2026

Tail Vein Transection Bleeding Model in Fully Anesthetized Hemophilia A Mice
08:13

Tail Vein Transection Bleeding Model in Fully Anesthetized Hemophilia A Mice

Published on: September 30, 2021

7.7K

Articular Bleeding in Hemophilia.

E Carlos Rodriguez-Merchan1

  • 1Department of Orthopaedic Surgery, La Paz University Hospital, Madrid, Spain.

Cardiovascular & Hematological Disorders Drug Targets
|January 5, 2017
PubMed
Summary
This summary is machine-generated.

Primary prophylaxis is key for individuals with hemophilia to prevent joint bleeds and degeneration. Prompt treatment with factor replacement or bypassing agents, alongside supportive therapies, minimizes long-term complications and preserves quality of life.

More Related Videos

A New Hybrid Quantitative Evaluation Model for Axillary Junctional Hemorrhage in Swine
08:27

A New Hybrid Quantitative Evaluation Model for Axillary Junctional Hemorrhage in Swine

Published on: December 6, 2024

713
Knee Arthrocentesis in Adults
04:41

Knee Arthrocentesis in Adults

Published on: February 25, 2022

10.1K

Related Experiment Videos

Last Updated: Mar 9, 2026

Tail Vein Transection Bleeding Model in Fully Anesthetized Hemophilia A Mice
08:13

Tail Vein Transection Bleeding Model in Fully Anesthetized Hemophilia A Mice

Published on: September 30, 2021

7.7K
A New Hybrid Quantitative Evaluation Model for Axillary Junctional Hemorrhage in Swine
08:27

A New Hybrid Quantitative Evaluation Model for Axillary Junctional Hemorrhage in Swine

Published on: December 6, 2024

713
Knee Arthrocentesis in Adults
04:41

Knee Arthrocentesis in Adults

Published on: February 25, 2022

10.1K

Area of Science:

  • Hematology
  • Orthopedics
  • Physical Therapy

Background:

  • Hemophilia management focuses on preventing joint bleeds (hemarthroses) and subsequent degeneration (hemophilic arthropathy).
  • Primary prophylaxis with factor replacement is the standard of care for persons with hemophilia (PWH).
  • Inhibitors to factor VIII or IX necessitate alternative treatments like bypassing agents.

Purpose of the Study:

  • To outline current strategies for managing hemarthroses in persons with hemophilia.
  • To emphasize the importance of early and comprehensive treatment to prevent long-term joint damage.
  • To discuss interventions for recurrent bleeds and their impact on quality of life.

Main Methods:

  • Review of established and emerging treatment protocols for hemophilia joint bleeds.
  • Emphasis on factor replacement therapy, bypassing agents (activated prothrombin complex concentrate, recombinant factor VIIa), and supportive care.
  • Inclusion of diagnostic (ultrasonography) and therapeutic (arthrocentesis, radiosynovectomy, arthroscopic synovectomy) procedures.

Main Results:

  • Early factor replacement or bypassing agent administration is crucial for acute hemarthroses.
  • Ultrasonography aids in confirming bleed resolution, minimizing long-term complications.
  • Rehabilitation and surgical interventions (radiosynovectomy, arthroscopic synovectomy) are vital for recurrent bleeds.

Conclusions:

  • Effective management of hemarthroses in hemophilia requires a multi-faceted approach, including prompt treatment and rehabilitation.
  • Preventing joint degeneration is essential for maintaining the health-related quality of life (HRQoL) in PWH.
  • While controversial, ice therapy and pain management play supportive roles in acute joint bleed management.